All news

Mesoblast stock set for board refresh as two directors depart

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Mesoblast is undergoing a board refresh as two directors, William Burns and Philip Krause, are departing. The company plans to recruit new directors with US and global commercial biopharma experience to support its commercial expansion following the US launch of Ryoncil, aiming to transition into a revenue-generating commercial enterprise.

Read original source

MESO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.